Context Therapeutics Shares Surge On Encouraging Data From Onapristone In Early Breast Cancer

Context Therapeutics Inc CNTX posted data from the window-of-opportunity trial of onapristone extended-release (ONA-XR) in postmenopausal patients with progesterone receptor-positive (PR+) early breast cancer. The data were presented at San Antonio Breast Cancer Symposium.

  • Two additional metastatic breast cancer clinical trials in progress were also presented.
  • The Phase 0 trial enrolled ten patients.
  • While no patients achieved a Complete Cell Cycle Arrest (CCCR), tumor Ki-67 expression decreased in six patients, remained stable in one patient, and increased in three patients. 
  • The mean percentage decrease of Ki67 for tumors with baseline PR expression over 90% (N=4) and less 90% (N=6) was -25.23% and 2.54%, respectively. 
  • Six patients reported adverse events, of which most were mild to moderate, including post-procedural pain, dry mouth, and an increase of gamma-glutamyl transferase (GGT). 
  • One patient experienced Grade 3 reversible GGT and aspartate aminotransferase (AST).
  • ONA-XR is being evaluated in four investigator-sponsored clinical trials in hormone-driven breast, ovarian and endometrial cancers.
  • The Company looks forward to data updates from three other ONA-XR trials in 2022.
  • Related Link: Context Therapeutics Shares Drop After Raising $31M Via Equity.
  • Price Action: CNTX shares are up 30.40% at $8.16 during the premarket session on the last check Friday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechLong IdeasNewsHealth CareMoversTrading IdeasGeneralbreast cancerBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!